Logotypy
Flaga Uni Europejskiej

The project has received funding from the European Union’s HORIZON 2022
research and innovation funding programme under Agreement No 881101.

BACTEROMIC

Learn about our system

BacterOMIC is a diagnostic system designed to address one of the most important challenges in modern medicine – multidrug resistance.

BacterOMIC consists of an Analyzer, Filling Device, and Panels for drug susceptibility assessment. As an automated system, it significantly simplifies and shortens laboratory procedures used in the evaluation of drug susceptibility of microorganisms.

The system allows phenotypic evaluation of the efficacy of 25 antibiotics used to treat respiratory, blood, urinary tract, or skin infections, among others.

Owing to the determination and expertise of a team of biotechnologists, engineers and software developers, and an innovative approach to the problem of modern diagnostics, a device has been created with considerable market potential and offering to revolutionize antibiotic treatment.

finalist
European Certificate
CE-IVD | ISO 13485

The BacterOMIC system has obtained European CE IVD certification granting it approval for sale on the European Union market.

The BacterOMIC project has been certified by the Polish Centre for Testing and Certification (‘PCBC’) as compliant with ISO 13485:2016.

BACTEROMIC Sp. z o.o.

The BacterOMIC system has been developed by the Scope Fluidics Group, which develops innovative medical diagnostic devices as part of its special purpose vehicle Bacteromic sp. z o.o.

Meet the Management Board of Bacteromic sp. z o.o.

piotr garstecki

Co-founder of Scope Fluidics. Chemistry professor and manager. He conducted scientific and technical projects in Poland and the United States, specializing in soft matter physics and microfluidic techniques. Passionate about the development of the organization and building value by creating technologies that solve important problems in health care.
Piotr Garstecki
President of the Management Board

piotr garstecki

Co-founder of Scope Fluidics. Manager. He gained experience in technology companies, research institutes and pharmaceutical companies. In his professional work, he coordinated a number of implementation processes. An enthusiast of risk management and solving difficult problems. At Scope Fluidics, he is responsible for clinical trials, intellectual property, production and registration processes.
Marcin Izydorzak
Vice-President

piotr garstecki

A manager with many years of experience in managing capital groups, implementing M&A transactions and cooperation with the capital market, including raising capital from international institutions. At Scope Fluidics, he is responsible for the financial department, M&A transactions and investor relations.
Szymon Ruta
Vice-President

BacterOMIC

BacterOMIC
A unique diagnostic solution

For doctors and patients

  • Logo Bacteromic
    Ensuring that clinicians have access to complete, i.e., practical, information on antibiotic susceptibility of pathogenic bacteria
  • Logo Bacteromic
    Accelerating access to precision antibiotic therapy
  • Logo Bacteromic
    Minimizing the risk of complications in treatment of bacterial infections
  • Logo Bacteromic
    Minimizing hospitalization time and treatment costs

Strengths

  • Logo Bacteromic
    640 incubation chambers per Panel
  • Logo Bacteromic
    One panel for Gram-positive and Gram-negative bacteria to simplify work and reduce confusion
  • Logo Bacteromic
    Analyzer’s capacity suitable for medium and large laboratories
  • Logo Bacteromic
    System equipped with simple interface software and expert system to interpret results according to current EUCAST recommendations
  • Logo Bacteromic
    Easy-to-use (manual procedure limited to pipetting the inoculum and closing Panel)
  • Logo Bacteromic
    Fully compatible with working standards in microbiology
  • Logo Bacteromic
    Automated to simplify the process and minimize errors
Laboratorium

Procedure for Use

Tests carried out in specialist diagnostic centres have confirmed the functionality of the BacterOMIC system in effectively identifying drug susceptibility of bacteria causing a range of infections. As emphasized by doctors and experts at the World Health Organisation (WHO), antibiotic resistance is one of the most serious problems in modern medicine.

technology

Procedure for Use

Isolated
bacterial strain

Monoculture
bacterial suspension

Transfer of suspension
to cartridge

Closure of cap

Placement of cartridges
in rack

Placement of
rack in
automatic filling unit

Single filling of up
to 10 cartridges

Transfer of filled
cartridges to Analyzer

Fully automated analysis
of up to 60 samples

bacteromic

BacterOMIC Analyzer

WIDTH 82,8 cm
HEIGHT 87,5 cm
DEPTH 59,5 cm
WEIGHT 79,5 kg
POWER SUPPLY 230 VAC 50 Hz 10 A
bacteromic

BacterOMIC Filling Device

WIDTH 32 cm
HEIGHT40 cm
DEPTH60 cm
WEIGHT41 kg
POWER SUPPLY230 VAC 50 Hz 8 A

BacterOMIC Diagnostic Panel

Effective antibiotic therapies

The BacterOMIC system enables single identification of the efficacy of a range of 25 antibiotics used in treatment of infections of the respiratory system, blood, urinary tract, or skin, among others. It is a rapid and accurate assessment of drug susceptibility of Gram-positive and Gram-negative bacteria in a single diagnostic panel.

Panel

BacterOMIC Panel UNI

Antibiotic

Microorganisms

Antibiotic

Microorganisms

Amikacin

Enterobacterales

Clarithromycin

Staphylococcus

Amoxicillin

Enterobacterales

Clindamycin

Enterococcus

Amoxicillin – clavulanic acid

Enterobacterales

Erythromycin

Enterococcus; Staphylococcus

Ampicillin

Enterobacterales

Gentamicin

Enterobacterales; Staphylococcus

Azithromycin

Staphylococcus

Levofloxacin

Acinetobacter; Enterobacterales; Enterococcus; Pseudomonas; Staphylococcus

Benzylpenicillin

Staphylococcus

Linezolid

Enterococcus; Staphylococcus

Cefazolin

Enterobacterales

Meropenem

Acinetobacter; Enterobacterales; Pseudomonas; Staphylococcus

Cefepime

Enterobacterales; Pseudomonas; Acinetobacter

Ofloxacin

Enterobacterales; Staphylococcus

Ceftazidime

Enterobacterales; Pseudomonas;

Tedizolid

Staphylococcus

Ceftazidime – Avibactam

Enterobacterales; Pseudomonas;

Tobramycin

Enterobacterales; Enterococcus; Pseudomonas

Ceftriaxone

Enterobacterales

Vancomycin

Enterococcus

Cefuroxime

Enterobacterales

Assessment of the presence of ESBL

Enterobacterales

Ciprofloxacin

Acinetobacter; Enterobacterales; Staphylococcus

Antibiotic

Amikacin

Amoxicillin

Amoxicillin – clavulanic acid

Ampicillin

Azithromycin

Benzylpenicillin

Cefazolin

Cefepime

Ceftazidime

Ceftazidime – Avibactam

Ceftriaxone

Cefuroxime

Ciprofloxacin

Microorganisms

Enterobacterales

Enterobacterales

Enterobacterales

Enterobacterales

Staphylococcus

Staphylococcus

Enterobacterales

Enterobacterales; Pseudomonas; Acinetobacter

Enterobacterales; Pseudomonas;

Enterobacterales; Pseudomonas;

Enterobacterales

Enterobacterales

Acinetobacter; Enterobacterales; Staphylococcus

Antibiotic

Clarithromycin

Clindamycin

Erythromycin

Gentamicin

Levofloxacin

Linezolid

Meropenem

Ofloxacin

Tedizolid

Tobramycin

Vancomycin

Assessment of the presence of ESBL

Microorganisms

Staphylococcus

Enterococcus

Enterococcus; Staphylococcus

Enterobacterales; Staphylococcus

Acinetobacter; Enterobacterales; Enterococcus; Pseudomonas; Staphylococcus

Enterococcus; Staphylococcus

Acinetobacter; Enterobacterales; Pseudomonas; Staphylococcus

Enterobacterales; Staphylococcus

Staphylococcus

Enterobacterales; Enterococcus; Pseudomonas

Enterococcus

Enterobacterales

Recipients

Laboratoria mikrobiologiczne

MICROBIOLOGY
LABORATORIES

Laboratoria centralne

CENTRAL
LABORATORIES

Szpitale

HOSPITALS

Technology

640 independent bacterial cultures in each single test

640 independent bacterial cultures in each single test

BacterOMIC is the world’s unique solution with the ultimate goal of being able to test as many as 640 bacterial culture conditions in a single test. This will translate into the capacity to compose a single test for the vast majority of clinically used antibiotics.

bacteromic technology
technology

OUR PATENTS

book

Microfluidic chip

EP 18189586.3

icon arrow

The invention is intended for microbiological testing cards, particularly for microbial identification and antimicrobial susceptibility testing (AST). It represents our core technology and protects the architecture of the microfluidic chip for microbiological testing. The microfluidic chip is covered by three patent applications in Europe, China, and the US.

book

Incubation segment with non-ventilated gas cavity in microfluidic chip

EP 3546565 B1

icon arrow

The object of the invention is the geometry of a single incubation segment in a microfluidic chip, suitable for microbiological research. The European Patent Office has decided to grant a patent for the invention, and it will soon be approved in 14 European countries. Two patent applications in the US and China are pending.

book

Method and system for rapid antimicrobial susceptibility testing

EP 3597768 B1

icon arrow

The invention protects a rapid signal analysis method of determining the minimum inhibitory concentration (MIC) based on standard measurements in the shortest possible time to date. Using the method, system or application, it is possible to reduce the incubation time of a standard antimicrobial susceptibility test (AST) using broth dilution, or to increase the precision of qualitative or quantitative antimicrobial susceptibility determinations. Patents for the invention have been issued in 14 European countries. In addition, two patent applications are pending in the US and China.

Unique combination of technologies used in the BacterOMIC system provides for a variety of potential applications

technology

Unique combination of technologies used in the BacterOMIC system provides for a variety of potential applications

Wykres

Did you know…?

Medicine
  • Logo Bacteromic
    The WHO has announced that antimicrobial resistance is one of the top 10 global public health threats facing humanity
  • Logo Bacteromic
    According to the latest data, the number of deaths related to antibiotic resistance in bacteria in 2019 was estimated at 4.95 million
  • Logo Bacteromic
    According to OECD data, antimicrobial resistance results in more than 700 million additional hospitalization days per year
  • Logo Bacteromic
    One of the main factors contributing to the development of antibiotic resistance is inappropriate selection and overuse of antibiotics

BacterOMIC project development timeline

timeline

Development of the BacterOMIC project over time

timeline
Scope Fluidics logo

Bacteromic is part of the
Scope Fluidics Group

We are developing the BacterOMIC project with a team of nearly 50 people working in a variety of specializations

Podwójne zdjęcie w laboratorium

E-MAIL US